Castle Biosciences Q2 FY26 net loss widens to $2.1 million; revenue rises 20.1% to $103.5 million - CSTL News | RalliesCastle Biosciences Q2 FY26 net loss widens to $2.1 million; revenue rises 20.1% to $103.5 million
C
CSTL• Q2 revenue rises while net loss widens
- Castle Biosciences posted Q2 revenue of $103.5 million, up 20.07% from a year earlier.
- Net results swung to a loss of $2.1 million; loss per share was $0.07.
- Adjusted EBITDA (non-GAAP) rose to $12.4 million; gross margin slipped 2.4 percentage points to 75%.
- Core test reports climbed 32% year over year, with TissueCypher volumes rising to 14,988.
- The company raised its 2026 revenue outlook to $365 million to $375 million and expects positive adjusted EBITDA in Q3, Q4, and full-year 2026.
WS
•
